A novel c-Met/EGFR bispecific targeting antibody drug conjugate for NSCLC

被引：1
|
作者：
Chen, Gang [1 ]
Li, Lingna [1 ]
Muyot, Pia [1 ]
Gros, Edwige [1 ]
Zhang, Yanliang [1 ]
Sun, Yingqing [1 ]
Zhang, Hong [1 ]
Fu, Yanwen [1 ]
Lee, Alice [1 ]
Cao, Jian [1 ]
Kaufmann, Gunnar [1 ]
Miao, Zhenwei [1 ]
机构：
[1] Concortis Biosyst, San Diego, CA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-LB-002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-002
引用
收藏
页数：3
相关论文
共 50 条
  • [31] JNJ-61186372, a novel EGFR/c-Met bispecific antibody, exhibits potent antitumor activity in broad-spectrum of acquired resistance to EGFR-TKIs
    Lee, SooHwan
    Yun, Jiyeon
    Jeong, Seo-Yoon
    Park, Chae Won
    Kim, Seok-Young
    Hong, Min Hee
    Kim, Hye Ryun
    Cho, Byoung Chul
    CANCER RESEARCH, 2020, 80 (16)
  • [32] 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
    Dokla, Eman M. E.
    Fang, Chun-Sheng
    Abouzid, Khaled A. M.
    Chen, Ching S.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 182
  • [33] Simultaneous inhibition of EGFR and c-Met pathways in a panel of NSCLC cell lines
    Blazek, E. R.
    Bonomi, P. D.
    Plate, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET
    Evers, Andreas
    Krah, Simon
    Demir, Deniz
    Gaa, Ramona
    Elter, Desislava
    Schroeter, Christian
    Zielonka, Stefan
    Rasche, Nicolas
    Dotterweich, Julia
    Knuehl, Christine
    Doerner, Achim
    MABS, 2024, 16 (01)
  • [35] SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
    Yang, Chang-yong
    Wang, Lei
    Sun, Xing
    Tang, Mi
    Quan, Hai-tian
    Zhang, Lian-shan
    Lou, Li-guang
    Gou, Shao-hua
    ACTA PHARMACOLOGICA SINICA, 2019, 40 (07) : 971 - 979
  • [36] SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
    Chang-yong Yang
    Lei Wang
    Xing Sun
    Mi Tang
    Hai-tian Quan
    Lian-shan Zhang
    Li-guang Lou
    Shao-hua Gou
    Acta Pharmacologica Sinica, 2019, 40 : 971 - 979
  • [37] Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
    Codony-Servat, J.
    Dotterweich, J.
    Molina-Vila, M. A.
    Roman, R.
    Gimenez-Capitan, A.
    Aldeguer, E.
    Rodriguez, S.
    Knuehl, C.
    Rosell, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S89 - S89
  • [38] cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors
    Min, Byeongkwi
    Jin, Jonghwa
    Kim, Hyeree
    Her, Nam-Gu
    Park, Changsik
    Kim, Donggeon
    Yang, Jehoon
    Hwang, Juhyeon
    Kim, Eunmi
    Choi, Minji
    Song, Ho Young
    Nam, Do-Hyun
    Yoon, Yeup
    ACS OMEGA, 2020, 5 (40): : 25798 - 25809
  • [39] Mechanistic characterization of MM-131, a bispecific antibody that blocks c-Met signaling through concurrent targeting of EpCAM
    Abu-Yousif, Adnan O.
    Casaletto, Jessica B.
    Masson, Kristina
    Fulgham, Aaron
    Geddie, Melissa
    Schoeberl, Birgit
    Nielsen, Ulrik
    MacBeath, Gavin
    CANCER RESEARCH, 2015, 75
  • [40] Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
    Zhuanglin Li
    Mingxue Wang
    Xuejing Yao
    Wenting Luo
    Yaocheng Qu
    Deling Yu
    Xue Li
    Jianmin Fang
    Changjiang Huang
    Targeted Oncology, 2019, 14 : 93 - 105
12345